![]() "Kite's relationship with the NKI, an internationally renowned cancer research and clinical institution, provides an important operational platform, as we advance TCR-based immuno-oncology product candidates. "With Kite Pharma EU, we have established a central hub of cancer immunotherapy efforts in Europe, attracting leading scientific experts, researchers and collaborators in this field," said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. Schumacher, a pioneer in T cell biology and gene therapy, is a developer of Kite's proprietary TCR-GENErator™ discovery platform, an industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates. Schumacher, who serves as Chief Scientific Officer of Kite Pharma EU. Kite Pharma EU is comprised of a leading team of immuno-oncology researchers and collaborators, including Professor Dr. Kite Pharma EU, based in Amsterdam, will be conducting preclinical research related to candidates under the agreement with NKI. "NKI believes that TCR technologies hold great potential for cancer care, and we are committed to making these new therapies a reality for patients." "We are excited with the progress of the TCR research programs with Kite and look forward to further advancements of the programs and our collaboration," said Professor René Medema, Director of NKI. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI. Today, we are the leader in cell therapy. Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. an exciting opportunity for a Cost Accountant to be based in Amsterdam. Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). For Current Kite Pharma Employees and Contractors: Please log onto your Internal. Kite and NKI Sign Master Services Agreement and Kite Obtains From NKI Exclusive Option to License T Cell Receptor (TCR) Cancer Immunotherapy Product Candidates.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |